Latest News

February 6, 2023
February 6, 2023
Categories

Ongoing Trial: The INSIGNA clinical trial is testing the timing of immunotherapy alone or with chemotherapy for patients with advanced lung cancer

Do you like it?
Read more
February 1, 2023
February 1, 2023
Categories

Ongoing Trial: The INSPIRE research study is testing a new treatment approach for patients with advanced bladder cancer

Do you like it?
Read more
January 30, 2023
January 30, 2023
Categories

Now Enrolling: The BRIDGE research study is evaluating a new treatment approach for patients with early bladder cancer

Do you like it?
Read more
January 24, 2023
January 24, 2023
Categories

Blinatumomab significantly improves overall survival in newly diagnosed B-ALL patients who are MRD-negative after initial treatment (study E1910)

Do you like it?
Read more
December 20, 2022
December 20, 2022
Categories

The November/December 2022 News from ECOG-ACRIN blog is now available

Do you like it?
Read more
Load more

Tweets

ECOG-ACRIN Cancer Research Group Follow

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

eaonc
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
20h

Do you have #AnalCancer that has spread to other parts of your body (also known as metastatic anal cancer)? If so, you may be able to participate in this study of a potential new treatment. Learn more: https://bit.ly/ea2176-study #ancsm #EndHPVCancers

Reply on Twitter 1623018960814850048 Retweet on Twitter 1623018960814850048 Like on Twitter 1623018960814850048 Twitter 1623018960814850048
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
21h

#Clinicaltrial EA8184 is evaluating if #greentea extract can be effective in reducing the progression of #prostatecancer in men on close monitoring. For more information: https://bit.ly/ea8184trial #pcsm cc: @jpowsang

Reply on Twitter 1623003788695969793 Retweet on Twitter 1623003788695969793 Like on Twitter 1623003788695969793 Twitter 1623003788695969793
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
21h

EA9152 is a phase Ib/II study of venetoclax in combination with vincristine sulfate in patients with relapsed or refractory T-cell or B-cell #ALL. For more information: https://bit.ly/EA9152 #leukemia #leusm cc: @SelinaLugerMD

Reply on Twitter 1622989350148403201 Retweet on Twitter 1622989350148403201 1 Like on Twitter 1622989350148403201 Twitter 1622989350148403201
Load More

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Home
57

Active Clinical Trials

Home
1300

Participating Institutions

Home
67

International Sites

Home
15000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group